This is important in view of the fact that combinations of VEGF inhibitors with other targeted therapies (i.e. mTOR inhibitors) in RCC have been hampered by increased toxicity and lack of clear greater clinical benefit as compared to single agents. This evidence concerns the gene MTOR and renal cell carcinoma.